tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CytoMed Launches Innovative CAR-T Cell Trial

CytoMed Launches Innovative CAR-T Cell Trial

CytoMed Therapeutics Limited (GDTC) has released an update.

Elevate Your Investing Strategy:

CytoMed Therapeutics Limited announced the initiation of the ANGELICA Trial, a Phase I clinical study testing innovative off-the-shelf CAR-T cell therapy using gamma delta T cells against blood and solid tumors, with financial backing from Singapore’s National Medical Research Council. In a strategic move to bolster its cell therapy capabilities, CytoMed also acquired a licensed cord blood bank in Malaysia, enhancing its foray into cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd. This acquisition promises to expand the company’s portfolio in treatments for aging diseases and regenerative medicine.

For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1